CPhI Online

- Market News

Alfasigma increases prefilled syringes and vials capacity with new sterile department at Alanno plant

27 Oct 2020

Italian pharma company Alfasigma has increased its capacity for production of pre-filled syringes with the 2020 launch of a new sterile department of excellence at its Alanno manufacturing plant.

The new department is completely dedicated to the production of pre-filled syringes, cartridges and ready-to-use vials, and is equipped with a high-performance, versatile filling line with an output of 36,000 pcs/h.

This high-quality manufacturing performance includes the option to use either peristaltic or volumetric pumps, the ability to manage oxygen-sensitive products, and accuracy in the plunger stopper placement and has 100% in-process control (IPC).

Fully integrated sterilization systems (ovens, autoclaves, passboxes) ensure the safety of the aseptic area in the line, according to top quality standard requirements.

All equipment is connected to a validated computer system in order to guarantee the complete traceability and integrity of the data.

Given its advanced technical characteristics, the new line is particularly suitable to supporting production processes requiring outstanding reliability for the manufacturing of high-value products such as biotechnology compounds, biosimilars and vaccines.

The expansion has increased Alfasigma’s overall annual production capacity to 150 million pre-filled syringes, which is welcome news given increased demand related to the current COVID-19 pandemic situation.

Alfasigma is a privately-owned, Italy-based integrated multinational pharmaceutical company with revenues in excess of €1 billion, five manufacturing plants, R&D facilities, and 3,000 employees globally. Outside of its core Italian market, Alfasigma has 16 subsidiaries in Europe, Asia, North and Central America and Africa, and is present in more than 90 countries.

The Alanno plant processes rifaximin, a molecule for the treatment of gastrointestinal disorders, which holds the record for US sales of an Italian-owned drug (over €1.5 billion euros, according to IQVIA).

Click here to download an infographic on Alfasigma's two new sterile departments at Alanno

Click here to download an infographic on Alfasigma's products and services


Related Content